This trial is active, not recruiting.

Condition esophageal cancer
Treatments loss of heterozygosity analysis, polymerase chain reaction, polymorphism analysis
Sponsor Eastern Cooperative Oncology Group
Collaborator National Cancer Institute (NCI)
Start date May 2007
Trial identifier NCT00898495, CDR0000551712, ECOG-E1201T1


RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a patient's response to treatment.

PURPOSE: This laboratory study is looking at genes to see if they can predict outcome in patients with esophageal cancer treated with cisplatin, radiation therapy, and surgery.

United States No locations recruiting
Other Countries No locations recruiting

Primary Outcomes

Histopathologic response (tumor present or completely absent) in the post-treatment resected specimen
time frame:
Comparison of pretreatment clinical tumor staging vs post-treatment pathologic staging (at resection)
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Diagnosis of adenocarcinoma of the esophagus - Stage I-IV disease - Received cisplatin-based treatment on clinical trial ECOG-1201 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified

Additional Information

Official title Single Nucleotide Polymorphisms (SNP) in Platinum-/Radiation Pathway Genes to Predict Outcome in Patients With Esophageal Adenocarcinoma Treated With Cisplatin-Based Chemoradiotherapy Followed by Surgical Resection
Description OBJECTIVES: - Correlate patient outcomes with neoplastic cell genotypes, specifically 18 single nucleotide polymorphisms (SNPs) in 16 major genes involved in platinum metabolism and disposition and DNA repair, in patients with esophageal cancer treated with neoadjuvant cisplatin-based chemoradiotherapy followed by surgical resection on clinical trial ECOG-1201. - Correlate patient outcomes with neoplastic cell genotypes, specifically loss of heterozygosity, in these patients. - Correlate patient outcomes with normal (germline) cell genotypes, specifically SNPs related to platinum metabolism and disposition and DNA repair. - Compare the predictive ability of neoplastic vs germline cell genotypes. OUTLINE: This is a retrospective, cohort, multicenter study. Neoplastic and normal (germline) cells are collected from pretreatment and post-treatment specimens using laser-capture microdissection. Single nucleotide polymorphisms are examined by real-time PCR. Loss of heterozygosity is assessed by analyzing short tandem repeat markers in neoplastic and germline tissue.
Trial information was received from ClinicalTrials.gov and was last updated in May 2009.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).